Table 2

Set of cards

Card	Preventing relapse	Preventing disease progression	Side effect risk	Route of administration	Frequency of administration
A	Presenting a relapse every 2 years	Preventing the disease from getting worse/progressing for 5 years	Rare but severe life-threatening side effects (including PML)	Oral	Daily
B	Presenting a relapse every 2 years	Preventing the disease from getting worse/progressing for 2 years	Frequent but mild/moderate side effects	Subcutaneous– intramuscular	Daily
C	Presenting a relapse every 5 years	Preventing the disease from getting worse/progressing for 5 years	Rare but severe life-threatening side effects (including PML)	Intravenous	Daily
D	Presenting a relapse every 5 years	Preventing the disease from getting worse/progressing for 2 years	Frequent but mild/moderate side effects	Oral	Every 2 days—weekly
E	Presenting a relapse every 2 years	Preventing the disease from getting worse/progressing for 5 years	Rare but severe life-threatening side effects (including PML)	Subcutaneous– intramuscular	Every 2 days—weekly
F	Presenting a relapse every 2 years	Preventing the disease from getting worse/progressing for 5 years	Rare but severe life-threatening side effects (including PML)	Oral	Monthly
G	Presenting a relapse every 5 years	Preventing the disease from getting worse/progressing for 2 years	Rare but severe life-threatening side effects (including PML)	Subcutaneous– intramuscular	Monthly
H	Presenting a relapse every 2 years	Preventing the disease from getting worse/progressing for 5 years	Frequent but mild/moderate side effects	Intravenous	Monthly
I	Presenting a relapse every 5 years	Preventing the disease from getting worse/progressing for 5 years	Frequent but mild/moderate side effects	Subcutaneous– intramuscular	Twice per year
J	Presenting a relapse every 2 years	Preventing the disease from getting worse/progressing for 2 years	Rare but severe life-threatening side effects (including PML)	Intravenous	Twice per year